All patients
age >= 55 yr age >= 60 yr age >= 65 yr autoimmune disease corticosteroids: no corticosteroids: yes critical disease invasive ventilation no oxygen needed non invasive oxygen omicron variant BA.1 (B.1.1.529) severe disease solid organ transplant recipients subjects at risk
anti-inflammatoty and immuno-therapy in COVID-19 severe or critically - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias 14-days deathsdetailed results Sekine (PLACOVID), 2021 2.14 [0.70; 6.58]
2.14 [0.70 ; 6.58 ] Sekine (PLACOVID), 2021 1 0% 160 NA not evaluable death D28detailed results AlQahtani, 2020 0.47 [0.04; 5.69]
CORIMUNO-TOCI-ICU (Group 2), 2020 0.64 [0.23; 1.80]
Jamaati, 2021 1.19 [0.38; 3.72]
Li, 2020 0.59 [0.22; 1.59]
Pouladzadeh, 2021 0.31 [0.01; 10.20]
Raman, 2021 0.49 [0.02; 15.10]
RECOVER, 2021 1.09 [0.38; 3.13]
Sekine (PLACOVID), 2021 1.38 [0.73; 2.62]
Shu, 2020 0.38 [0.02; 8.14]
Tabarsi, 2020 1.10 [0.45; 2.67]
Talaschian, 2021 1.56 [0.34; 7.13]
Veiga, 2021 2.70 [0.92; 7.92]
1.10 [0.79 ; 1.53 ] AlQahtani, 2020, CORIMUNO-TOCI-ICU (Group 2), 2020, Jamaati, 2021, Li, 2020, Pouladzadeh, 2021, Raman, 2021, RECOVER, 2021, Sekine (PLACOVID), 2021, Shu, 2020, Tabarsi, 2020, Talaschian, 2021, Veiga, 2021 12 0% 983 moderate low deathsdetailed results AlQahtani, 2020 0.47 [0.04; 5.69]
CAPSID, 2021 0.84 [0.28; 2.50]
CODEX (Tomazini), 2020 0.97 [0.72; 1.31]
CORIMUNO-TOCI-1 (Group 1), 2020 0.92 [0.31; 2.71]
CORIMUNO-TOCI-ICU (Group 2), 2020 0.64 [0.23; 1.80]
CP-COVID-19, 2021 3.20 [0.62; 16.39]
Darazam (COVIFERON Interferon beta-1a), 2021 0.31 [0.07; 1.25]
Darazam (COVIFERON Interferon beta-1b), 2021 0.52 [0.14; 1.92]
DEXA-COVID19, 2020 2.00 [0.21; 18.87]
Jamaati, 2021 1.19 [0.38; 3.72]
Li, 2020 0.59 [0.22; 1.59]
Pouladzadeh, 2021 0.31 [0.01; 10.20]
Rahmani, 2020 0.29 [0.05; 1.56]
Raman, 2021 0.49 [0.02; 15.10]
Rasheed, 2020 0.13 [0.01; 1.09]
RECOVER, 2021 1.09 [0.38; 3.13]
REMAP-CAP (plasma), 2021 0.96 [0.80; 1.15]
REMAP-CAP (tocilizumab), 2021 0.70 [0.51; 0.95]
Sekine (PLACOVID), 2021 1.38 [0.73; 2.62]
Shu, 2020 0.38 [0.02; 8.14]
Steroids-SARI, 2020 0.91 [0.29; 2.86]
Tabarsi, 2020 1.10 [0.45; 2.67]
Talaschian, 2021 1.25 [0.30; 5.14]
Veiga, 2021 2.70 [0.92; 7.92]
0.91 [0.80 ; 1.03 ] AlQahtani, 2020, CAPSID, 2021, CODEX (Tomazini), 2020, CORIMUNO-TOCI-1 (Group 1), 2020, CORIMUNO-TOCI-ICU (Group 2), 2020, CP-COVID-19, 2021, Darazam (COVIFERON Interferon beta-1a), 2021, Darazam (COVIFERON Interferon beta-1b), 2021, DEXA-COVID19, 2020, Jamaati, 2021, Li, 2020, Pouladzadeh, 2021, Rahmani, 2020, Raman, 2021, Rasheed, 2020, RECOVER, 2021, REMAP-CAP (plasma), 2021, REMAP-CAP (tocilizumab), 2021, Sekine (PLACOVID), 2021, Shu, 2020, Steroids-SARI, 2020, Tabarsi, 2020, Talaschian, 2021, Veiga, 2021 24 0% 4,607 moderate low deaths (time to event analysis only)detailed results CP-COVID-19, 2021 3.20 [0.62; 16.39]
Talaschian, 2021 1.25 [0.30; 5.14]
1.87 [0.64 ; 5.45 ] CP-COVID-19, 2021, Talaschian, 2021 2 0% 140 moderate not evaluable clinical deteriorationdetailed results CAPSID, 2021 0.63 [0.29; 1.40]
CODEX (Tomazini), 2020 0.66 [0.43; 1.02]
CORIMUNO-TOCI-1 (Group 1), 2020 0.56 [0.26; 1.20]
Shu, 2020 0.27 [0.01; 5.58]
0.63 [0.45 ; 0.88 ] CAPSID, 2021, CODEX (Tomazini), 2020, CORIMUNO-TOCI-1 (Group 1), 2020, Shu, 2020 4 0% 575 moderate not evaluable clinical improvementdetailed results CAPSID, 2021 1.58 [0.71; 3.49]
Darazam (COVIFERON Interferon beta-1a), 2021 2.36 [1.09; 5.12]
Li, 2020 1.40 [0.79; 2.49]
Pouladzadeh, 2021 7.31 [1.62; 32.97]
REMAP-CAP (tocilizumab), 2021 1.64 [1.25; 2.15]
Sekine (PLACOVID), 2021 0.94 [0.74; 1.19]
Shu, 2020 10.27 [1.17; 90.18]
1.67 [1.12 ; 2.50 ] CAPSID, 2021, Darazam (COVIFERON Interferon beta-1a), 2021, Li, 2020, Pouladzadeh, 2021, REMAP-CAP (tocilizumab), 2021, Sekine (PLACOVID), 2021, Shu, 2020 7 72% 1,264 moderate serious clinical improvement (14-day)detailed results Li, 2020 2.27 [0.90; 5.72]
Shu, 2020 10.27 [1.17; 90.18]
3.46 [0.92 ; 13.03 ] Li, 2020, Shu, 2020 2 36% 144 moderate not evaluable clinical improvement (28-day)detailed results Li, 2020 1.42 [0.65; 3.10]
Pouladzadeh, 2021 7.31 [1.62; 32.97]
Sekine (PLACOVID), 2021 0.94 [0.74; 1.19]
Shu, 2020 3.68 [0.18; 75.54]
1.66 [0.75 ; 3.67 ] Li, 2020, Pouladzadeh, 2021, Sekine (PLACOVID), 2021, Shu, 2020 4 64% 364 moderate not evaluable clinical improvement (7-day)detailed results Li, 2020 0.98 [0.27; 3.58]
Shu, 2020 6.72 [1.50; 30.07]
2.47 [0.37 ; 16.27 ] Li, 2020, Shu, 2020 2 72% 144 moderate not evaluable clinical improvement (time to event analysis only)detailed results Darazam (COVIFERON Interferon beta-1a), 2021 2.36 [1.09; 5.12]
Darazam (COVIFERON Interferon beta-1b), 2021 1.42 [0.63; 3.18]
Li, 2020 1.40 [0.79; 2.49]
Rahmani, 2020 3.41 [1.33; 8.73]
1.83 [1.24 ; 2.70 ] Darazam (COVIFERON Interferon beta-1a), 2021, Darazam (COVIFERON Interferon beta-1b), 2021, Li, 2020, Rahmani, 2020 4 9% 249 moderate not evaluable death or ventilationdetailed results CORIMUNO-TOCI-1 (Group 1), 2020 0.56 [0.24; 1.31]
Veiga, 2021 1.54 [0.65; 3.63]
0.93 [0.35 ; 2.49 ] CORIMUNO-TOCI-1 (Group 1), 2020, Veiga, 2021 2 63% 260 moderate not evaluable hospital dischargedetailed results Rahmani, 2020 3.44 [0.64; 18.49]
3.44 [0.64 ; 18.49 ] Rahmani, 2020 1 0% 66 NA not evaluable mechanical ventilationdetailed results AlQahtani, 2020 0.67 [0.22; 2.02]
Darazam (COVIFERON Interferon beta-1a), 2021 1.00 [0.27; 3.67]
Darazam (COVIFERON Interferon beta-1b), 2021 1.00 [0.27; 3.67]
Jamaati, 2021 1.38 [0.45; 4.20]
Rahmani, 2020 0.29 [0.05; 1.56]
Shu, 2020 0.59 [0.02; 14.04]
Tabarsi, 2020 1.49 [0.59; 3.78]
0.98 [0.61 ; 1.57 ] AlQahtani, 2020, Darazam (COVIFERON Interferon beta-1a), 2021, Darazam (COVIFERON Interferon beta-1b), 2021, Jamaati, 2021, Rahmani, 2020, Shu, 2020, Tabarsi, 2020 7 0% 361 moderate not evaluable mechanical ventilation (time to event analysis only)detailed results CP-COVID-19, 2021 0.66 [0.25; 1.72]
0.66 [0.25 ; 1.72 ] CP-COVID-19, 2021 1 0% 100 NA not evaluable radiologic improvement (14-day)detailed results Jamaati, 2021 4.89 [1.15; 20.79]
Tabarsi, 2020 2.33 [0.45; 12.00]
3.53 [1.19 ; 10.46 ] Jamaati, 2021, Tabarsi, 2020 2 0% 134 moderate not evaluable viral clearance detailed results CP-COVID-19, 2021 1.12 [0.16; 7.84]
Raman, 2021 36.42 [10.85; 122.18]
6.97 [0.23 ; 210.35 ] CP-COVID-19, 2021, Raman, 2021 2 89% 200 moderate not evaluable viral clearance by day 14detailed results CP-COVID-19, 2021 1.51 [0.33; 6.94]
Raman, 2021 36.42 [10.85; 122.18]
7.68 [0.34 ; 173.70 ] CP-COVID-19, 2021, Raman, 2021 2 90% 200 moderate not evaluable ICU admissiondetailed results CP-COVID-19, 2021 0.82 [0.35; 1.91]
Darazam (COVIFERON Interferon beta-1a), 2021 1.00 [0.21; 4.71]
Darazam (COVIFERON Interferon beta-1b), 2021 0.46 [0.11; 1.94]
Rahmani, 2020 0.37 [0.14; 1.00]
Tabarsi, 2020 0.56 [0.18; 1.74]
0.60 [0.36 ; 0.98 ] CP-COVID-19, 2021, Darazam (COVIFERON Interferon beta-1a), 2021, Darazam (COVIFERON Interferon beta-1b), 2021, Rahmani, 2020, Tabarsi, 2020 5 0% 330 moderate not evaluable recoverydetailed results Talaschian, 2021 0.64 [0.14; 2.92]
0.64 [0.14 ; 2.92 ] Talaschian, 2021 1 0% 36 NA not evaluable serious adverse eventsdetailed results CODEX (Tomazini), 2020 0.53 [0.17; 1.62]
Raman, 2021 0.49 [0.02; 15.10]
REMAP-CAP (plasma), 2021 2.28 [1.17; 4.46]
Sekine (PLACOVID), 2021 1.14 [0.88; 1.48]
Talaschian, 2021 7.93 [0.37; 171.38]
Veiga, 2021 1.66 [0.60; 4.59]
1.33 [0.84 ; 2.10 ] CODEX (Tomazini), 2020, Raman, 2021, REMAP-CAP (plasma), 2021, Sekine (PLACOVID), 2021, Talaschian, 2021, Veiga, 2021 6 36% 2,704 moderate not evaluable superinfectiondetailed results Rahmani, 2020 0.18 [0.02; 1.59]
0.18 [0.02 ; 1.59 ] Rahmani, 2020 1 0% 66 NA not evaluable adverse eventsdetailed results Raman, 2021 1.36 [0.56; 3.30]
Sekine (PLACOVID), 2021 1.08 [0.85; 1.38]
Shu, 2020 2.48 [0.05; 132.54]
Veiga, 2021 1.65 [0.81; 3.37]
1.14 [0.92 ; 1.43 ] Raman, 2021, Sekine (PLACOVID), 2021, Shu, 2020, Veiga, 2021 4 0% 430 moderate not evaluable 0.0 10.0 1.0 relative treatment effect www.metaEvidence.org 2024-10-02 07:55 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 91
- treatments: 546,564,944,682,1266,943,894,560,1102,598,563,668,753,752,836,639,541,534,581,615,679,522,582,666,1149,1150,737,544,733,597,524,611,538,957,958,521,566,517,881,904,882,897,896,899,1235,898,687,740,883,947,536,591,729,887,742,878,975,570,771,888,1141,690,880,1255,567,596,1437,600,652,557,635,1236,553,628,646,645,607,395,920,1438,927,932,931,1263,599,614,942,1436,928,923,535,1046,727,818,606,954,964,962,963,1045,638,677,627,533,526,616,926,1246,726,580,568,527,588,539,585,691,1210,525
- roots T: 290